CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- 4 Planned sale Chief Commercial Officer sold 10,000 shares at $11.00 ($110,000)
- 4 Planned sale Chief Commercial Officer sold 339 shares at $9.21 ($3,122)
- 4 Planned sale Chief Operating Officer sold 2,257 shares at $9.08 ($20,483)
- 4 Planned sale Chief Legal Officer sold 2,256 shares at $9.38 ($21,160)
- 4 Option exercise President and CEO acquired 6,103 shares (option exercise)
- 4 Option exercise Director acquired 10,000 shares (option exercise)
- 4 Open-market sale Chief Commercial Officer sold 6,414 shares at an average $8.46 ($54,266)
- 4 Open-market sale Chief Operating Officer sold 1,813 shares at $8.46 ($15,339)
- 4 Open-market sale Chief Medical Officer sold 8,180 shares at $8.46 ($69,209)
- 4 Open-market sale SVP, Finance & Accounting sold 7,142 shares at $8.46 ($60,426)
- 4 Open-market sale Chief Scientific Officer sold 1,311 shares at $8.46 ($11,092)
- 4 Open-market sale Chief Legal Officer sold 11,208 shares at $8.46 ($94,828)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Medical Officer acquired 50,000 shares (grant or award)
- 4 Grant or award SVP, Finance & Accounting acquired 21,250 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 50,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Commercial Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
- 4 Open-market sale Chief Scientific Officer sold 23,726 shares at $9.78 ($231,931)
Page 2 of 14 · 275 filings